Business Context and Reporting Period
Company: ORAMED PHARMACEUTICALS INC.
Filing Type: Form 8-K (Current Report)
Date of Report: May 30, 2013
Event: Award of a government grant to the company's wholly owned Israeli subsidiary, Oramed Ltd.
Key Financial Metrics
Grant Amount: NIS 975,000 (approximately $265,000 USD).
Source: Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel.
Revenue/Profit/Cash Flow: The filing text does not provide a clear value for overall revenue, profit, cash flow, margins, debt, or liquidity metrics for the period.
Material Changes and Grant Terms
- Usage of Funds: Designated to support R&D and clinical studies for oral insulin capsule (ORMD-0801) and oral exenatide capsule (ORMD-0901) from January 2013 to December 2013.
- Repayment Obligation: Oramed Ltd. is required to pay royalties at a rate of 3% – 5% on sales of products and services derived from the technology developed using this grant.
- Repayment Condition: Royalties are due until the full dollar amount of the grants is repaid, plus interest. No payment is required in the absence of such sales.
Guidance, Outlook, and Risks
Outlook: The grant supports ongoing clinical development for the company's lead candidates (ORMD-0801 and ORMD-0901).
Risks/Contingencies: Future financial obligations are contingent upon successful commercialization. If products derived from the technology generate sales, the company must pay royalties plus interest. If no sales occur, no repayment is required.
Investor Verification Checklist
- Verify the exact exchange rate used to convert NIS 975,000 to USD at the time of the announcement.
- Confirm the specific milestones or deliverables required by the OCS to release the grant funds.
- Review the company's pipeline status for ORMD-0801 and ORMD-0901 to assess the likelihood of future sales triggering royalty payments.
- Check subsequent filings for the actual receipt of funds and any updates on the clinical study progress.